BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ChemBridge Corporation Announces Their New Fragment Library For Screening


1/10/2007 10:00:54 AM

SAN DIEGO, Jan. 10 /PRNewswire/ -- ChemBridge has assembled an exemplary collection of small molecules useful for fragment-based screening: the new Fragment Library. The emergence and development of high throughput X-ray crystallography and NMR methodologies for drug discovery have contributed widely to the acceptance and implementation of fragment based screening. The ability to detect low affinity binders has proven invaluable in the introduction and promotion of this aspect of drug discovery and design. The Fragment Library set, comprising approximately 12,000 compounds, was chosen based upon the commonly accepted Astex "Rule-of-Three" (MW <300, H-bond donors/acceptors <3, cLogP <3) as well as the established proprietary ChemBridge substructure filters. The set includes compounds with available, as well as protected, functionality. All compounds in the collection are available in stock and may be cherry-picked or taken as a complete set.

Upon independent analysis of ChemBridge's Fragment Library, an industry expert from a well respected pharmaceutical company regards the collection as both attractive and diverse, commenting that it is the largest commercial fragment library currently offered to his knowledge.

"The fragment collection has been assembled using industry standard chemometrics coupled with ChemBridge's knowledge of small molecule pharmacophore profiling," said ChemBridge's Reg Richardson, Ph.D. "The result is the largest commercial offering of 'discovery chemistry-relevant' small molecule fragments. I am certain the Fragment Library will be valuable to those engaged in fragment based screening to identify and construct new chemical entities having excellent lead-like properties."

About ChemBridge Corporation

ChemBridge Corporation, www.chembridge.com, is a leading global discovery chemistry CRO with an impeccable track record of quality and deliverability. ChemBridge was founded in Chicago in 1993 and has grown to a global company with 350 employees. ChemBridge has its corporate headquarters in San Diego, European office in the UK, and a marketing agency in Japan. It also operates a large, state-of-the-art offshore discovery chemistry research site in Moscow, Russia. Over 400 pharmaceutical and biotech companies and universities worldwide have taken advantage of ChemBridge's portfolio of advanced discovery chemistry services and products, including its library of 700,000 diverse drug-like small molecule compounds.

ChemBridge Corporation

CONTACT: Reg Richardson, Ph.D. of ChemBridge Corporation, +44 (0)1386765-519, sales@chembridge.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES